Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.

Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.

J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):245-51. doi: 10.2459/JCM.0b013e32832180d9.

PMID:
19262211
2.

The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.

Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group.

Catheter Cardiovasc Interv. 2012 May 1;79(6):956-64. doi: 10.1002/ccd.23165. Epub 2011 Dec 12.

PMID:
22162050
3.

Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Zijlstra F, van 't Hof AW.

J Am Coll Cardiol. 2004 Sep 15;44(6):1187-93.

4.

Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.

Zhang Q, Wang XL, Liao ML, Hu J, Yang ZK, Ding FH, Zhang JS, Du R, Zhu TQ, Shen WF, Zhang RY.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:762-9. doi: 10.1002/ccd.25864.

PMID:
25630513
6.

Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.

Nikolsky E, Holmes DR, Mehran R, Dangas G, Schampaert E, Morice MC, Schofer J, Sousa JE, Fahy M, Na Y, Donohoe DJ, Moses JW, Leon MB.

Catheter Cardiovasc Interv. 2008 Jun 1;71(7):896-906. doi: 10.1002/ccd.21548.

PMID:
18498145
7.

Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.

Uyarel H, Uzunlar B, Unal Dayi S, Tartan Z, Samur H, Kasikcioglu H, Akgul O, Simsek D, Erdem I, Okmen E, Cam N.

Cardiology. 2006;105(3):168-75. Epub 2006 Feb 13.

PMID:
16479104
8.

Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).

Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, Schanzenbächer P, Ertl G, Voelker W.

J Am Coll Cardiol. 2002 Aug 21;40(4):662-8.

9.
10.
11.

Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.

Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N.

Angiology. 2006 May-Jun;57(3):273-81.

PMID:
16703187
12.

Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.

Martínez-Ríos MA, Rosas M, González H, Peña-Duque MA, Martínez-Sánchez C, Gaspar J, García H, Gaxiola E, Delgado L, Carrillo J, Leyva JL, Lupi E; SASTRE Investigators.

Am J Cardiol. 2004 Feb 1;93(3):280-7. Erratum in: Am J Cardiol. 2004 Jul 1;94(1):150.

PMID:
14759375
13.
14.

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, Moro PJ, Lambert M, Alessi MC, Bonnet JL.

JACC Cardiovasc Interv. 2008 Dec;1(6):649-53. doi: 10.1016/j.jcin.2008.08.018.

16.

Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.

Akbulut M, Ozbay Y, Gundogdu O, Dagli N, Durukan P, Ilkay E, Arslan N.

Curr Med Res Opin. 2004 Nov;20(11):1759-67.

PMID:
15537476
17.

Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Kırma C, Erkol A, Pala S, Oduncu V, Dündar C, İzgi A, Tigen K, Gibson CM.

Catheter Cardiovasc Interv. 2012 Jan 1;79(1):59-67. doi: 10.1002/ccd.23109. Epub 2011 Nov 30.

PMID:
21523892
18.

Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.

Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM.

Indian Heart J. 2012 Sep-Oct;64(5):444-8. doi: 10.1016/j.ihj.2012.07.022. Epub 2012 Jul 27.

20.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.

PMID:
12588269

Supplemental Content

Support Center